A federal district judge in Rochester, N.Y., has given four insulin and diabetes drug manufacturers until Oct. 29 to file a motion to dismiss an upstate New York health center’s lawsuit claiming the manufacturers conspired to stop offering 340B pricing when covered entities use contract pharmacies.
U.S. Chief District Judge Elizabeth Wolford gave the health center, Mosaic Health, until Dec. 17 to file papers opposing the companies’ attempt to scuttle its case. The companies—AstraZeneca, Lilly, Novartis, and Sanofi—have until Jan. 14, 2022, to file any replies to Mosaic’s opposition. Wofford issued the scheduling order setting the October, December, and January deadlines late last month.
A federal district judge in Rochester, N.Y., has given four insulin and diabetes drug manufacturers until Oct. 29 to file a motion to dismiss an upstate New York health center’s lawsuit claiming the manufacturers conspired to stop offering 340B pricing when covered entities use contract pharmacies.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
